Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]

Eur J Cancer. 2017 Jan:70:156. doi: 10.1016/j.ejca.2016.11.001. Epub 2016 Dec 3.

Affiliations

¹ Ruspharmtech LLC, Saint Petersburg, Russia. Electronic address: [email protected].
² Altogen Labs, Austin, TX, USA.
³ N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
⁴ FD Computing, Beerse, Belgium.
⁵ EcoSynth, Oostende, Belgium.
⁶ Moscow Clinical and Research Center, Moscow, Russia.

PMID: 27919550
DOI: 10.1016/j.ejca.2016.11.001

No abstract available

Publication types

Published Erratum